Vudalimab for Neoplasm Metastasis

Phase-Based Progress Estimates
Northwestern University, Chicago, IL
Neoplasm Metastasis+6 More
Vudalimab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing an immunotherapy drug to see if it can shrink tumors in patients with certain types of thyroid cancer. Vudalimab is being used to treat Neoplasm Metastasis in a clinical trial. This is not the first time Vudalimab has been approved by the FDA, as it has been previously approved for a different condition. In this trial, no patients will receive a placebo.

Eligible Conditions

  • Neoplasm Metastasis
  • Thyroid Gland

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Neoplasm Metastasis

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Up to 5 years

At 16 weeks
Day 30
Incidence of adverse events
Up to 5 years
Clinical benefit rate
Duration of clinical benefit(DoCB)
Duration of response
Objective response rate (ORR)
Overall survival (OS)
Progression-free survival (PFS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Neoplasm Metastasis

Trial Design

1 Treatment Group

Treatment (vudalimab)
1 of 1
Experimental Treatment

54 Total Participants · 1 Treatment Group

Primary Treatment: Vudalimab · No Placebo Group · Phase 2

Treatment (vudalimab)
Experimental Group · 1 Intervention: Vudalimab · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years
Closest Location: Northwestern University · Chicago, IL
Photo of Northwestern University 1Photo of Northwestern University 2Photo of Northwestern University 3
1993First Recorded Clinical Trial
11 TrialsResearching Neoplasm Metastasis
1052 CompletedClinical Trials

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
12,937 Previous Clinical Trials
41,301,951 Total Patients Enrolled
217 Trials studying Neoplasm Metastasis
24,120 Patients Enrolled for Neoplasm Metastasis
Northwestern UniversityLead Sponsor
1,422 Previous Clinical Trials
717,631 Total Patients Enrolled
6 Trials studying Neoplasm Metastasis
2,105 Patients Enrolled for Neoplasm Metastasis
Jochen H Lorch, M.D.Principal InvestigatorNorthwestern University

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Subjects who have received and failed, or are intolerant to, a BRAF/MEK inhibitor (e.g., dabrafenib or trametinib) must enroll in the trial.
Subjects must have a histologically confirmed diagnosis of Hurthle cell thyroid cancer (HCC)
You have Hurthle cell thyroid cancer (HCC) that is incurable, metastatic HCC.
Subjects with HCC must have previously received and failed, or be intolerant to, at least one line of primarily anti-VEGFR tyrosine kinase inhibitor therapy (e.g.
You must meet all general inclusion criteria.
Subjects with HCC must have demonstrated radiographic disease progression within =< 14 months prior to enrollment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.